NASDAQ:MLYS • US6031701013
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MINERALYS THERAPEUTICS INC (MLYS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-19 | Stifel | Maintains | Buy -> Buy |
| 2025-11-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-03 | Jefferies | Maintains | Hold -> Hold |
| 2025-08-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-11 | Jefferies | Initiate | Hold |
| 2025-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-13 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-10 | HC Wainwright & Co. | Initiate | Buy |
| 2024-04-02 | Goldman Sachs | Initiate | Buy |
| 2023-08-08 | Credit Suisse | Maintains | Outperform -> Outperform |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 115.35% | N/A 190.35% | N/A 67.56% | N/A 34.50% | N/A 22.29% | N/A 13.45% | |||||||
| EBITDA YoY % growth | N/A | N/A | N/A | N/A -189.20% | -192.36M -107.59% | -170.545M 11.34% | N/A -14.58% | N/A -1.75% | N/A 97.50% | N/A 3,612.13% | N/A 287.90% | N/A 70.47% | N/A 42.04% | N/A 31.67% | |
| EBIT YoY % growth | -2.943M | -18.725M -536.26% | -31.479M -68.11% | -84.657M -168.93% | -192.403M -127.27% | -170.604M 11.33% | N/A -11.54% | N/A -20.30% | N/A 106.29% | N/A 1,631.32% | N/A 158.16% | N/A 52.95% | N/A 31.75% | N/A 16.51% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -2.00 46.36% | -3.64 -82.00% | -2.37 34.89% | N/A 4.09% | N/A -18.84% | N/A 77.72% | N/A 533.90% | N/A 115.23% | N/A 37.21% | N/A 26.42% | N/A 11.85% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.47 40.24% | -0.50 23.83% | -0.53 -2.00% | -0.60 -50.09% | -0.60 -26.39% | -0.58 -15.65% | -0.62 -16.35% | -0.62 -2.79% |
| Revenue Q2Q % growth | 12.24M | 16.32M | 34.68M | |||||
| EBITDA Q2Q % growth | -42.536M 4.27% | -44.453M 4.84% | -45.46M -10.65% | -50.033M -30.90% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -42.512M 4.35% | -45.741M 2.15% | -48.737M -18.49% | -55.477M -44.93% | -53.601M -26.08% | -52.989M -15.85% | -57.273M -17.51% | -57.885M -4.34% |
All data in USD
15 analysts have analysed MLYS and the average price target is 50.36 USD. This implies a price increase of 89.19% is expected in the next year compared to the current price of 26.62.
MINERALYS THERAPEUTICS INC (MLYS) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of MINERALYS THERAPEUTICS INC (MLYS) is -0.47 USD and the consensus revenue estimate is 0 USD.